Discontinued — last reported Q3 '25

Non-Current Liabilities

Debt Maturity - 2027

Roivant Sciences Debt Maturity - 2027 decreased by 1.0% to $10.00M in Q4 2025 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryLiquidity
SignalLower is better
VolatilityStable
First reportedQ1 2016
Last reportedQ3 2025

How to read this metric

Higher values indicate a larger cash requirement in 2027, which may affect liquidity or require refinancing.

Detailed definition

This metric represents the total principal amount of debt obligations scheduled to mature during the calendar year 2027....

Peer comparison

Standardized across all public companies; peers disclose this in debt maturity tables.

Metric ID: debt_maturity_2027

Historical Data

2 periods
 Q3 '25Q4 '25
Value$10.10M$10.00M
QoQ Change—-1.0%
Range$10.00M – $10.10M

Debt Maturity - 2027 at Other Companies

Viatris logo
ViatrisVTRSView metric
Merck & Co. logo
Merck & Co.MRKView metric
IQVIA logo
IQVIAIQVView metric

Frequently Asked Questions

What is Roivant Sciences's debt maturity - 2027?
Roivant Sciences (ROIV) reported debt maturity - 2027 of $10.00M in Q4 2025.
What does debt maturity - 2027 mean?
The amount of debt principal due for repayment in 2027.